SG11201912195TA - Peptide immunogens from the c-terminal end of alpha-synuclein protein and formulations thereof for treatment of synucleinopathies - Google Patents

Peptide immunogens from the c-terminal end of alpha-synuclein protein and formulations thereof for treatment of synucleinopathies

Info

Publication number
SG11201912195TA
SG11201912195TA SG11201912195TA SG11201912195TA SG11201912195TA SG 11201912195T A SG11201912195T A SG 11201912195TA SG 11201912195T A SG11201912195T A SG 11201912195TA SG 11201912195T A SG11201912195T A SG 11201912195TA SG 11201912195T A SG11201912195T A SG 11201912195TA
Authority
SG
Singapore
Prior art keywords
synucleinopathies
formulations
alpha
treatment
terminal end
Prior art date
Application number
SG11201912195TA
Other languages
English (en)
Inventor
Chang Yi Wang
Original Assignee
United Neuroscience
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United Neuroscience filed Critical United Neuroscience
Publication of SG11201912195TA publication Critical patent/SG11201912195TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/563—Immunoassay; Biospecific binding assay; Materials therefor involving antibody fragments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
SG11201912195TA 2017-06-16 2018-06-15 Peptide immunogens from the c-terminal end of alpha-synuclein protein and formulations thereof for treatment of synucleinopathies SG11201912195TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762521287P 2017-06-16 2017-06-16
PCT/US2018/037938 WO2018232369A1 (en) 2017-06-16 2018-06-15 Peptide immunogens from the c-terminal end of alpha-synuclein protein and formulations thereof for treatment of synucleinopathies

Publications (1)

Publication Number Publication Date
SG11201912195TA true SG11201912195TA (en) 2020-01-30

Family

ID=64659951

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201912195TA SG11201912195TA (en) 2017-06-16 2018-06-15 Peptide immunogens from the c-terminal end of alpha-synuclein protein and formulations thereof for treatment of synucleinopathies

Country Status (10)

Country Link
US (1) US20210138049A1 (enrdf_load_html_response)
EP (1) EP3638298A4 (enrdf_load_html_response)
JP (3) JP2021508672A (enrdf_load_html_response)
KR (2) KR20240150813A (enrdf_load_html_response)
AU (1) AU2018283510B8 (enrdf_load_html_response)
BR (1) BR112019026707A2 (enrdf_load_html_response)
CA (1) CA3067231A1 (enrdf_load_html_response)
MX (1) MX2019015286A (enrdf_load_html_response)
SG (1) SG11201912195TA (enrdf_load_html_response)
WO (1) WO2018232369A1 (enrdf_load_html_response)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3051839A1 (en) 2017-02-17 2018-08-23 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
SG11202003624SA (en) 2017-10-27 2020-05-28 United Neuroscience Tau peptide immunogen constructs
CA3125286A1 (en) * 2018-12-28 2020-07-02 United Biomedical, Inc. Peptide immunogens targeting interleukin 6 (il-6) and formulations thereof for immunotherapy of diseases impacted by il-6 dysregulation
IL298215A (en) 2020-05-19 2023-01-01 Othair Prothena Ltd Multi-epitope vaccine for the treatment of alzheimer's disease
MX2023001483A (es) * 2020-08-04 2023-03-08 Ac Immune Sa Compuestos inmunogenicos.
KR20230087487A (ko) * 2020-09-17 2023-06-16 프로테나 바이오사이언시즈 리미티드 시누클레인 병증을 치료하기 위한 α-시누클레인 백신
KR102505164B1 (ko) * 2020-09-29 2023-02-28 서울대학교산학협력단 신경퇴행성 질환의 예방 또는 치료용 펩타이드 및 이를 포함하는 약학 조성물
JPWO2022265091A1 (enrdf_load_html_response) 2021-06-18 2022-12-22
MX2024002684A (es) * 2021-09-01 2024-05-16 Vaxxinity Inc Metodos para la prevencion y tratamiento de sinucleinopatias.
CN119053345A (zh) 2022-02-28 2024-11-29 特瑞德姆生物科技有限责任两合公司 由至少一种β-葡聚糖或甘露聚糖组成或包含至少一种β-葡聚糖或甘露聚糖的偶联物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6906169B2 (en) * 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
US7358331B2 (en) * 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
US20120142902A1 (en) * 2007-02-23 2012-06-07 The Regents Of The University Of California Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
DK2949666T3 (en) * 2008-12-19 2019-03-25 Biogen Int Neuroscience Gmbh HUMAN ANTI-ALPHA SYNUCLEIN ANTIBODIES
WO2013173827A2 (en) * 2012-05-18 2013-11-21 Board Of Regents Of The University Of Nebraska Methods and compositions for inhibiting diseases of the central nervous system
JP2015527369A (ja) * 2012-08-21 2015-09-17 インスティテュート フォー モレキュラー メディシン， インコーポレイテッド アミロイド、タウおよびα−シヌクレインの沈着に関連する疾患に関する組成物および方法
US9102752B2 (en) * 2013-03-15 2015-08-11 United Biomedical, Inc. Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type
US20170184612A1 (en) * 2014-04-09 2017-06-29 The Trustees Of Columbia University In The City Of New York Use of leukocytes and novel biomarkers in the diagnosis, confirmation, and treatment of a neurological disorder
US10155030B2 (en) * 2014-05-23 2018-12-18 University Of South Florida Methods, antibodies, and vaccines utilizing epitopes of alpha synuclein for treatment of parkinsons disease

Also Published As

Publication number Publication date
WO2018232369A1 (en) 2018-12-20
AU2018283510B8 (en) 2025-09-18
JP2025090637A (ja) 2025-06-17
AU2018283510A1 (en) 2020-01-16
JP2023082018A (ja) 2023-06-13
BR112019026707A2 (pt) 2020-06-30
JP2021508672A (ja) 2021-03-11
RU2020101121A3 (enrdf_load_html_response) 2021-10-15
EP3638298A4 (en) 2021-05-05
RU2020101121A (ru) 2021-07-16
JP7732676B2 (ja) 2025-09-02
CA3067231A1 (en) 2018-12-20
KR20240150813A (ko) 2024-10-16
AU2018283510B2 (en) 2025-06-26
KR20200054938A (ko) 2020-05-20
EP3638298A1 (en) 2020-04-22
MX2019015286A (es) 2020-08-17
US20210138049A1 (en) 2021-05-13

Similar Documents

Publication Publication Date Title
SG11201912195TA (en) Peptide immunogens from the c-terminal end of alpha-synuclein protein and formulations thereof for treatment of synucleinopathies
IL322464A (en) Methods and compositions for administering therapeutic protein
IL275777A (en) Improved peptide drugs for the treatment of NASH and other disorders
SG11201702813VA (en) Pharmaceutical formulations for the oral delivery of peptide or protein drugs
HUE057083T2 (hu) C-típusú nátriuretikus peptid változatainak alkalmazása oszteoartritisz kezelésére
ZA201905851B (en) Peptides and methods for the treatment of diabetes
EP3829597A4 (en) TRIMER PEPTIDES FOR ANTISENSE ADMINISTRATION
SG11202005526WA (en) Peptide immunogens of il-31 and formulations thereof for the treatment and/or prevention of atopic dermatitis
IL290520A (en) Medicinal peptides
SG11202104178TA (en) Peptides and pharmaceutical compositions for treating eye diseases
IL285144A (en) Medicinal peptides
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
IL281513A (en) Pharmaceutical compositions suitable for articular delivery and use thereof in treatment of joint pain
HUE059500T2 (hu) Aminosavakat tartalmazó készítmények elhízás kezelésében történõ alkalmazásra
IL277734A (en) Application of short PEDF-derived peptides in the treatment of osteoarthritis
ZA201904386B (en) S-arrestin peptides and therapeutic uses thereof
ZA202100587B (en) Peptide compounds and therapeutic uses of same
IL282519A (en) Peptide fragments for the treatment of diabetes
IL275690A (en) Nanoparticles for targeted delivery of therapeutic polypeptides
HUE059593T2 (hu) Rekombináns hGH-t tartalmazó gyógyszerkészítmény növekedési hormon hiányának kezelésére
IL280066A (en) Injection techniques to treat cellulite
SG11202106847SA (en) Conotoxin peptide analogs and uses for the treatment of pain and inflammatory conditions
EP3628048A4 (en) PEPTIDES FOR CANCER TREATMENT
IL281091A (en) Peptide therapy for cancer treatment and their uses
IL276824A (en) Compositions and methods for administration and expression of small inhibitory peptides and their use